IMDX - imdxinc.com Company Long-Term Debts

Graphic logo of Insight Molecular Diagnostics, Inc. (IMDX)

Insight Molecular Diagnostics (IMDX) is advancing molecular diagnostics by sourcing consumables from partners while maintaining full control over the execution of genetic tests. This chart of the share price confirms the current trend, with long-term debt standing at 0.00. The company is recognized as an expert in personalized medicine due to its ultra-precise research. The business's financial stability remains high, ensuring the confident fulfillment of all payment obligations and the preservation of capital.

IMDX Insight Molecular Diagnostics, Inc.: Company Long-Term Debts in the range 06/19/2025 - 10/28/2026

Financial and market metric breakdowns for Insight Molecular Diagnostics Inc (IMDX)

- price and consensus price forecast:
Share Price Insight Molecular Diagnostics, Inc.|IMDX - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Insight Molecular Diagnostics|IMDX - Total Company Value
- book capitalization data:
Equity per Share Insight Molecular Diagnostics|IMDX - Book Capitalization|Market Capitalization to Book Value Ratio imdxinc.com|IMDX - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Insight Molecular Diagnostics|IMDX - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Insight Molecular Diagnostics, Inc.|IMDX - Company Debts|Debts to Net Assets Insight Molecular Diagnostics|IMDX - Company Long-Term Debts|Short-Term Debt Volume Insight Molecular Diagnostics
General company analysis:IMDX (Insight Molecular Diagnostics)
Mass-produced product of imdxinc.com

Insight Molecular Diagnostics (IMDX) maintains stability by retaining highly skilled bioinformaticians through investments in cutting-edge equipment and diagnostic precision. The total volume of liabilities with a maturity of over one year determines the company's financial leverage, where the corporation's long-term loan and credit chart demonstrates a balance between hedging against interest rate risks and scaling operational activities.

Competing companies

Company Long-Term Indebtedness agilent.com A|Quest Diagnostics Incorporated - Company Long-Term Debts|ILMN: Company Long-Term Debts|Company Long-Term Debt Cologuard|Revvity Corp (RVTY) - Company Long-Term Indebtedness|BIO (Bio-Rad Laboratories) - Company Long-Term Debts|Company Long-Term Debts NNNN|Company Long-Term Debt Sotera Health (SHC)|Company Long-Term Debt Quidel Corporation QDEL|OPK: Company Long-Term Liabilities|CareDx - Long-Term Debt|Company Long-Term Debt MRVI (Maravai LifeSciences)|FLGT - Long-Term Debt Volume|Standard BioTools - Company Long-Term Debts|CTKB (Cytek Biosciences Inc) - Long-Term Debt Volume|OSUR: Company Long-Term Debt|Long-Term Debt Volume Exagen Diagnostics|MDXH (MDxHealth SA) - Company Long-Term Debts|Long-Term Debt Volume LUCD (luciddx.com)|PRE - Company Long-Term Debt|Trinity Biotech PLC - Company Long-Term Indebtedness|Company Long-Term Debt PRPH (ProPhase)|AIMD - Long-Term Debt Volume|Co-Diagnostics, Inc. - Company Long-Term Debts|heartsciences.com (HSCS) - Long-Term Debt Volume|Biomerica - Company Long-Term Debts|Long-Term Indebtedness Cardio Diagnostics Holdings, Inc.|Virax Biolabs Group Ltd (VRAX) - Company Long-Term Debts|Company Long-Term Loans and Borrowings Bluejay Diagnostics Corp BJDX|Company Long-Term Liabilities Aspira Women's Health (AWH)|AXDX - Amount of Long-Term Liabilities|Company Long-Term Liabilities CENTOGENE (CNTG)|ENZ: Company Long-Term Loans and Borrowings|FRES (fresh2.co) - Company Long-Term Debt|GENE (Genetic Technologies Limited) - Company Long-Term Liabilities|Company Long-Term Debt ME (23andMe Holding Co.)|Long-Term Debt PMD